ICON CLINICAL RESEARCH (U.K.) LIMITED

Their core work

ICON Clinical Research UK is the British arm of ICON plc, one of the world's largest contract research organizations (CROs) that runs clinical trials on behalf of pharmaceutical, biotech, and medical device sponsors. They handle the operational machinery of drug development: patient recruitment, trial site management, regulatory submissions, data monitoring, and biostatistics across Phase I through Phase IV studies. Within H2020 consortia, they appear as a third-party service provider — the team that actually executes the clinical trial components when academic consortia need industrial-grade trial operations. Their value in research projects is turning a scientific protocol into an audit-ready, multi-country clinical study.

What they specialise in

How they've shifted over time

In their earlier H2020 work (2015 onward, MIROCALS), the focus was on immunomodulatory small-molecule approaches to neurodegenerative disease — classic pharmacology in a Phase II setting. From 2017-2018, their portfolio shifted toward advanced therapy medicinal products, running trials for PLX-PAD placental cell therapies across two different indications (chronic limb ischemia in PACE, hip fracture recovery in HIPGEN). The trajectory moves from conventional drug trials into the more complex ATMP/cell therapy trial space, and from Phase II into Phase III.

They are deepening capability in advanced cell therapy trials at Phase III scale — valuable for any consortium planning late-stage ATMP studies in elderly or trauma populations.

How they like to work

ICON never coordinates and never acts as a named beneficiary — they participate exclusively as a third party (contracted service provider) to the consortium. They fit into large, multi-country academic-industrial consortia, delivering the clinical operations piece while scientific leadership sits with clinicians and biotechs. Working with them means buying professional trial execution rather than gaining a scientific co-author.

Connected to 32 distinct consortium partners across 13 countries over just three projects, reflecting the geographically distributed nature of multi-center clinical trials. Their footprint is pan-European with the usual clinical-trial hub countries (UK, France, Germany, Israel) anchoring each study.

What sets them apart

Most H2020 health consortia stitch together hospital-based trial sites and university statisticians; ICON offers the alternative — a single industrial CRO that can run the entire trial with GCP-grade SOPs from day one. For consortia without a commercial sponsor, bringing ICON in as a third party de-risks the clinical execution leg, particularly for ATMP and late-phase studies where regulatory compliance is unforgiving. They are the partner you add when the science is ready but the trial operations capability inside the consortium is not.

Highlights from their portfolio

• MIROCALS
  A rare randomized Phase II trial of an immunomodulator in ALS — one of the most difficult neurodegenerative indications to run a trial in.
• HIPGEN
  Phase III study of a placental cell therapy for hip fracture recovery in elderly patients — combining late-stage ATMP complexity with a frail trial population.
• PACE
  Phase IIb with HLA-unmatched allogeneic placenta-derived stromal cells — a technically demanding ATMP trial at EU scale.